Edesa jumped more than 44% on heavy volume after licensing its ARDS drug candidate paridiprubart to Japan’s KYORIN Pharmaceutical for $12 million upfront and up to about $134 million in milestones.
Investorideas.com (www.investorideas.com) a trusted platform for investing ideas, including biotech and medical tech stocks, issues a news and trading alert for Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases.
The stock is trading at $3.0900 +0.9500 (+44.39%) on volume of over 74 Million shares making the Nasdaq top gainers list following news. The stock has a day’s high of $3.93.
Edesa Biotech, Inc. (Nasdaq: EDSA) and KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), a leading Japanese pharmaceutical company, today announced that they have entered into an exclusive collaboration and license agreement for the development and commercialization of paridiprubart in Japan.
Advertisement
Under the terms of the agreement, Kyorin will obtain an exclusive license to further develop and commercialize Edesa’s drug candidate, paridiprubart, in Japan, in Acute Respiratory Distress Syndrome (ARDS). Edesa will receive an upfront payment of $12 million and is eligible to receive additional development, regulatory and sales-based milestones up to approximately $134 million, a portion of which is denominated in Japanese yen. Edesa is also eligible to receive tiered double-digit royalties on net sales of the product in Japan. Kyorin will fund development, regulatory and commercialization activities in Japan for the treatment of ARDS and has been granted a right of first negotiation for acute kidney injury (AKI) and a non-exclusive right to negotiate for other potential indications. Edesa will manufacture and supply product to Kyorin and the parties will coordinate development activities. Edesa retains all rights to paridiprubart outside of Japan. Japan is one of the world’s largest pharmaceutical markets, accounting for approximately 4 to 5 percent of global pharmaceutical spending.
Paridiprubart is a monoclonal antibody candidate that targets toll-like receptor 4, a key regulator of the innate immune response. In a Phase 3 study in hospitalized patients with respiratory failure, paridiprubart plus standard of care demonstrated a statistically significant reduction in 28-day mortality compared to placebo (adjusted mortality risk of 39% versus 52%; p<0.001), a treatment benefit that was sustained at 60 days (p=0.003) and accompanied by a safety profile comparable to placebo. Positive exploratory analyses showed consistent survival benefits in less severe patients not on invasive mechanical ventilation and in subgroups with serious comorbidities, including acute kidney injury. These results were selected for oral presentations at the American Thoracic Society and the European Renal Association.
Dr. Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech, stated, “We believe Kyorin’s experience with respiratory treatments and their extensive footprint in Japan make them a strong partner for the continued development and commercialization of paridiprubart, our potential first-in-class antibody. For Edesa shareholders, we believe this deal represents a validation of our business model and the ability to share in the future success of this drug candidate.”
Yutaka Ogihara, President and CEO of KYORIN Pharmaceutical Co., Ltd., stated, “We are pleased, as a company with a strong foundation in respiratory medicine, to secure the exclusive rights to develop and commercialize EB05 in Japan, an innovative therapeutic candidate for ARDS – an extremely severe condition that requires intensive care. Conquering ARDS represents one of the most formidable frontiers in drug discovery, but that is precisely why it is profoundly meaningful for KYORIN to proactively take on this challenge. Together with Edesa, by uniting our scientific passion, specialized expertise, and relentless driving force, we will dramatically accelerate global clinical development, including in Japan, to bring new hope to patients and healthcare professionals in critical care settings as expeditiously as possible.”
Research biotech stocks at the free stock directory at Investorideas.com
Learn more about becoming a featured annual biotech stock or be featured in a trading alert
https://www.investorideas.com/bis/stock_list.asp
Disclaimer/Disclosure: Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published/created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer and disclosure info: https://www.investorideas.com/about/disclaimer.asp
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/about/private_policy.asp
Disclaimer / Disclosure: InvestorIdeas.com is a digital publisher of financial content and is not a registered investment adviser or broker-dealer. This article is informational and is not a recommendation to buy or sell any security; some content may be sponsored or compensated. See our full disclaimer.
